Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

NCT IDNCT07071155ClinicalTrials.gov data as of Apr 2026

Check if I qualify Back to results ClinicalTrials.gov

Phase

EARLY_PHASE1

Ages

18–100

Locations

1 site in MD

Why this study is shown

Matches myelodysplastic syndromesActively enrollingEARLY_PHASE1

What this study is about

This EARLY_Phase 1 study is testing Azacitidine in people with chronic myelomonocytic leukemia.

Simplified from trial records by PatientMatch.

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel

In-person visits

Requires travel to a study site

Physical Intervention

Injection / IVsubcutaneous

How treatment is administered

Treatment Assignment

Standard assignment

Assignment is predetermined by the study protocol.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

azacitidine, momelotinib

Drug routes

injection, subcutaneous, oral (Oral Tablet)

Endpoints

Secondary: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), Number of participants who experience a grade 3 or higher adverse events or severe event, Patient Global Impression of Change (PGIC)

Body systems

Oncology

Screen for this study View on ClinicalTrials.gov